Affordable drugs, especially those with low-profit margins, risk cessation of production in the United States if pharmaceutical tariffs are implemented under the Trump administration. Pharmaceuticals, many of which are imported, are a daily necessity for combating ailments ranging from common infections to serious diseases like cancer, and for alleviating pain. However, if Trump’s projected tariffs on foreign-produced medicine are actualized, these medicines may become scarce, transforming the typical doctor consultation and potentially compromising patient care, according to professionals in the field. For instance, if a hefty tariff is enforced, production of cost-effective but low profit drugs, such as the elements in epidurals, could be discontinued.
An example consequence of this situation might be that patients would need to resort to substitute treatments due to the hospital experiencing certain drug shortages. An expert on drug shortages speculates, “Possibly, not everyone will have access to an epidural anymore. We might find ourselves going backwards in medical history.” Up to this point, pharmaceuticals had somehow avoided being embroiled in Trump’s escalating trade conflict globally. Despite Trump’s announcement in April, colloquially known as ‘Liberation Day’, to severely tax imports from foreign countries, pharmaceuticals were not included.
Nonetheless, it seems this exemption might not last much longer. Since his reelection, Trump has consistently expressed the belief that if he were to launch tariffs on pharmaceuticals, this could exert enough pressure to coax manufacturers to relocate their operations back to the United States. He has declared, “We are on the verge of proclaiming a major pharmaceutical tariff.” Additionally, in April, an investigation was announced by the Department of Commerce into the potential national security risks of importing pharmaceuticals, possibly laying the groundwork for the imposition of tariffs on drugs as a countermeasure.
Dreadfully worried about such a prospect, pharmacists in the U.S. have already begun to amass reserves of the most commonly dispensed drugs. The obscurity of the medication supply chain implies that it is undeterminable which drugs would be the hardest hit by tariffs. Notwithstanding, it is worth considering which categories of drugs could be the most susceptible to dissipation if a severe pharmaceutical tariff were to be executed, affecting those most in need.
The majority of over-the-counter pain relief medication acquired in the U.S. is originally sourced from China. Consequently, you would not immediately note the absence of these drugs due to the existence of stockpiles. However, were the tariffs to go into effect at the start of June, one could realistically anticipate some scarcities emerging by the time of traditional holidays such as Halloween and Christmas.
Most prescriptions dispensed in the U.S. are for generic drugs, a significant portion of which are produced overseas. Basic, everyday hospital-used generic injectable drugs such as lidocaine and morphine are economical to manufacture but could be left vulnerable to discontinuation under a substantial tariff as companies might opt to produce more profitable drugs. Cancer treatments are an additional category of drugs that generate concern regarding the ramifications of significant pharmaceutical tariffs.
Worries over potential shortages in hospitals rise due to the influence of major pharmaceutical tariffs. These drugs have already proven problematic regarding supply availability. A critical chemotherapy medication known as Cisplatin encountered a shortage in 2023, due to manufacturing quality deficiencies in an Indian facility. This facility had a 50% market share of the drug, illustrating how a single hitch in the supply chain can have a domino effect.
The earlier disruption in the supply of Cisplatin in 2023 occurred due to quality-oriented issues, but if Trump implements universal pharmaceutical tariffs, this could lead to supply shortages motivated by economic factors. Most cancer treatments must be managed by physicians and many of them are covered under the “340B” safety-net program of the U.S. government. This program enables eligible hospitals and other healthcare providers to purchase certain outpatient drugs from manufacturers at highly discounted rates.
The 340B program is intended to enhance access to outpatient medicines but could also result in rendering the production of cancer drugs unprofitable for manufacturers, especially in the wake of tariffs ranging from 20% to 25%. As for the prospect of constructing medicine factories in the U.S., it’s unlikely to materialize in the foreseeable future as it typically demands a minimum of three years due to the intricate regulations and inspections imposed by the Food and Drug Administration.
Hospital administered drugs are often dispensed in vials that require syringes, the majority of which are manufactured in China. A tariff exclusively targeting China might stimulate other countries, such as India, to lessen their dependence on Chinese active pharmaceutical ingredients. This could consequently be beneficial for the U.S. which heavily relies on importing various products from India.
However, a comprehensive tariff covering India as well would heighten the probability of generic drug shortages and stimulate India into sourcing from more economical Chinese providers. Preserving his stance, Trump continues to vouch for his tariff trade policy. If Trump decides to impose a 25% tariff on all imported pharmaceuticals, this will indubitably leave a mark in history.
Nevertheless, facing a future with limited access to preferred or required medical treatments resulting from drug shortages is a reality we would much prefer not to recall. When winter descends and a cold strikes, there’s a possibility that the medicines you’ve been depending on may no longer be stocked on the shelves. It’s an alarming prospect that underlines the necessity for careful, patient-focussed decision making in these complex trade tussles over tariffs and pharmaceuticals.
The post Pharmaceutical Tariffs Threaten Access to Essential Medicines appeared first on Real News Now.
About Author
